Recent Advances in AI & Multi-Omics for Translational Research
AI-driven multi-omics integration; translational research; precision medicine; biomarker discovery; patient stratification; machine learning; foundation models; agentic AI; cancer research; drug response prediction
AstraZeneca Onshores Rare Disease Portfolio as Part of $50B US Investment Pledge
AstraZeneca; rare disease portfolio; onshoring; US investment; biomanufacturing; $50 billion pledge; Virginia facility; Maryland investment; R&D expansion
Sandoz Launches Afqlir (Aflibercept) in Europe, Increasing Access to Affordable Retinal Disease Treatment
Sandoz; Afqlir; aflibercept; biosimilar; retinal diseases; neovascular age-related macular degeneration (nAMD); European Commission approval; Eylea; anti-VEGF therapies; affordable treatment; vision loss; Europe
As Drug Resistance Rises, GramEye and GSK Advance New AI-Led Infectious Disease Research
antimicrobial resistance (AMR); GramEye; GSK; AI-driven drug discovery; Gram-negative bacteria; Staphylococcus aureus; fungal infections; novel antibiotics; superbugs; infectious disease research; clinical trials
GSK and AnaptysBio Enter Legal Dispute Over Jemperli License Amid Allegations of Contract Breaches
GSK; AnaptysBio; Jemperli; dostarlimab; TESARO; litigation; license agreement; oncology; royalties; endometrial cancer
Eli Lilly Becomes First Drugmaker to Reach $1 Trillion Valuation
Eli Lilly; trillion-dollar valuation; weight-loss drugs; Mounjaro; Zepbound; GLP-1 market; pharmaceutical industry; stock market; market capitalization
FDA Breakthrough Designations Lead to Priority Reviews, Report Finds
FDA; breakthrough therapy designation; priority review; drug approval; expedited pathway; biotechnology innovation; rare diseases; oncology; CDER; regulatory science
FDA Grants Regeneron Two Eylea HD Approvals in One Day
Regeneron; FDA approval; Eylea HD; macular edema; retinal vein occlusion; monthly dosing; aflibercept; ophthalmology; RVO
Aspen Neuroscience Secures $115 Million Series C to Advance Parkinson’s Cell Therapy; IPO Considered for 2026
Aspen Neuroscience; Series C financing; Parkinson’s disease; cell therapy; ANPD001; autologous iPSC; clinical trials; manufacturing scale-up; IPO plans; regenerative medicine
Edgewise Therapeutics Appoints Christopher Martin to its Board of Directors
Edgewise Therapeutics; Christopher Martin; Board of Directors; biotech executive; commercial leadership; Becker muscular dystrophy; cardiovascular asset; Verona Pharma; Merck acquisition